Media Room

Contact Information
Intervet
Schering-Plough Animal Health
Global Communications
Media Relations
+31 485 587 600
communications@intervet.com

Schering-Plough
About The Company
Schering-Plough News & Media
Investor Relations
Corporate Responsibility

Management
Ruurd Stolp, President

Press Releases- 2006

Date	Description
15 Nov 2006	Intervet appoints Jochen Bader Vice President Finance and Control Intervet, the animal health business unit of Akzo Nobel, appointed the current Director Finance and Control, Jochen Bader (46), Vice President Finance and Control. After graduating from ‘Fachhochschule’ ...
15 Nov 2006	Intervet appoints Malte Greune as a member of the company's Executive Committee Intervet, Akzo Nobel’s veterinary pharma business, announces that Malte Greune (41) has been appointed as a member of Intervet’s Executive Committee. Malte Greune will succeed Joost Helsen in the function ...
15 Nov 2006	Intervet benoemt Jochen Bader tot Vice President Finance and Control Intervet, het veterinair farmaceutische dochterbedrijf van Akzo Nobel, heeft de huidige Director Finance and Control Jochen Bader (46) benoemd als Vice President Finance and Control. Na het afronden van ...
15 Nov 2006	Intervet benoemt Malte Greune als directielid Intervet, het veterinair farmaceutische dochterbedrijf van Akzo Nobel, heeft Malte Greune (41) aangesteld als directielid. Malte Greune volgt Joost Helsen op in de functie van Vice President Manufacturing ...
15 Nov 2006	Intervet ernennt Jochen Bader zum Vice President Finance and Control Intervet, das veterinär-pharmazeutische Tochterunternehmen von Akzo Nobel, hat den derzeitigen Director Finance and Control Jochen Bader (46) zum Vice President Finance and Control ernannt. Nach dem Abschluss ...
15 Nov 2006	Intervet ernennt Malte Greune zum Direktionsmitglied Intervet, das veterinär-pharmazeutische Tochterunternehmen von Akzo Nobel, hat Malte Greune (41) als Direktionsmitglied eingestellt. Malte Greune tritt in der Funktion des Vice President Manufacturing ...
4 Oct 2006	Intervet appoints Ellen de Brabander as a member of the company’s Executive Committee Intervet, Akzo Nobel’s veterinary pharma business, announces that Ellen de Brabander – van den Berg (43) has been appointed as a member of Intervet’s Executive Committee, effective October 1, 2006. Ellen ...
14 Sep 2006	Intervets paardenvaccin tegen West-Nijlvirus goedgekeurd in de VS Een vaccin, dat is ontwikkeld door Akzo Nobels diergeneeskundige activiteit Intervet, bestemd voor paarden die de kans lopen besmet te raken met het West-Nijlvirus, is door de United States Department ...
14 Sep 2006	Intervets West-Nil-Impfstoff für Pferde von USDA zugelassen Ein Impfstoff, der von Intervet, Akzo Nobels Geschäftsbereich für Tiergesundheit, entwickelt wurde und bei Pferden gegen das West-Nil-Virus eingesetzt wird, ist vom US-Ministerium für Landwirtschaft (USDA) ...
14 Sep 2006	Intervet’s equine West Nile vaccine approved by USDA An equine vaccine developed by Akzo Nobel’s animal health business Intervet, which is indicated for use in horses at risk from West Nile virus has been approved by the United States Department of Agriculture ...
1 Sep 2006	Intervet’s avian flu vaccine licensed for use in European Union Intervet’s vaccine is based on a different strain (H5N2) than the current field strain (H5N1). Birds vaccinated with H5N2 form a different set of antibodies than those birds infected with H5N1. These ...
1 Sep 2006	Vogelgriepvaccin van Intervet krijgt EU-registratie Intervet, ‘s werelds grootste producent van vaccins voor dieren en een dochterbedrijf van Akzo Nobel, heeft een EU-registratie gekregen voor zijn vaccin Nobilis Influenza H5N2. Hierdoor beschikt Europa ...
21 Aug 2006	Intervet krijgt goedkeuring FDA voor Zilmax® Boxmeer, 21 augustus, 2006 –– De Amerikaanse Food and Drug Administration (FDA) heeft Intervet in de Verenigde Staten (Intervet Inc.) goedkeuring gegeven voor Zilmax (zilpaterol hydrochloride). Dit product ...
21 Aug 2006	Intervet Receives FDA Approval for Zilmax Intervet’s U.S. business (Intervet Inc.) has received approval from the U.S. Food and Drug Administration (FDA) for Zilmax (zilpaterol hydrochloride), a product designed to improve production efficiencies ...
27 Jul 2006	Intervet continues to invest in Saxe Gotha business park in Boxmeer On 27 July 2006, Intervet purchased the Plukon site at Saxe Gotha business park in Boxmeer. Covering over four hectares, the site is located opposite Intervet’s facilities. Thanks to this purchase, Intervet ...
27 Jul 2006	Intervet investeert verder op industrieterrein Saxe Gotha in Boxmeer Op 27 juli 2006 heeft Intervet het Plukon-terrein op industrieterrein Saxe Gotha in Boxmeer aangekocht. Dit terrein is ruim vier hectare groot en ligt tegenover de faciliteiten van Intervet. Met deze ...
25 Jul 2006	Citing Special Need, USDA Issues Conditional License for Poultry Industry’s First Vaccine for Necrotic Enteritis Schering-Plough Animal Health Now Field Testing Product in USSchering-Plough Animal Health Corporation has obtained a conditional license from the U.S. Department of Agriculture to begin field testing ...
5 Jul 2006	Foot-and-Mouth disease vaccine factory now owned by Intervet Five months after signing an agreement on sale and purchase the Foot-and-Mouth (FMD) vaccine factory in Cologne Bayer HealthCare AG and Intervet International bv have completed the acquisition. Both ...
5 Jul 2006	Intervet International bv nu eigenaar van productiefaciliteit voor vaccin tegen Mond- en Klauwzeer van Bayer HealthCare AG Vijf maanden na de overeenkomst voor de acquisitie van de productiefaciliteit voor MKZ-vaccin in Keulen, Duitsland, hebben Bayer HealthCare AG en Intervet International bv de acquisitie afgesloten. Beide partijen ...
12 Jun 2006	Intervet develops prototype for mass application avian influenza vaccine A biotech breakthrough achieved by Akzo Nobel’s animal health business, Intervet, means that mass application of a dual vaccine against avian influenza and Newcastle Disease could be available in the ...
12 Jun 2006	Intervet entwickelt Prototyp für den Masseneinsatz von Vogelgrippe-Impfstoffen Ein biotechnischer Durchbruch von Intervet, Akzo Nobels Geschäftsfeld für Tiergesundheit bedeutet, dass der Masseneinsatz einer kombinierten Impfung gegen die Vogelgrippe und die Newcastle-Krankheit in ...
12 Jun 2006	Intervet ontwikkelt prototype voor grootschalige toepassing vogelgriepvaccin Door een biotechnologische doorbraak van Intervet, Akzo Nobels activiteit op het gebied van veterinaire gezondheidszorg, zou er in de nabije toekomst een duovaccin tegen vogelgriep en pseudovogelpest ...
29 May 2006	Intervet Dieter Lütticken Award - Intervet’s award to reduce the number of animals used in testing for development and production of animal veterinary medicines Intervet International bv offers the Dieter Lütticken award to promote scientists or life science research institutions working in research areas that serve the 3R-concept i.e. reducing, refining or replacing ...
1 May 2006	NEW! Japan’s Ministry of Health, Labor and Welfare (MHLW) Implements New Regulations Similar to U.S. regulations regarding residues of agricultural chemicals in food Schering-Plough Animal Health556 Morris Avenue Summit, New Jersey 07901 (908) 473-3336 Luis Fernandez, Senior ...
27 Apr 2006	Intervet levert vogelgriepvaccins aan Duitse dierentuinen Op initiatief van een aantal deelstaten heeft Duitsland toestemming van de Europese Unie gekregen om vogels in dierentuinen in te enten tegen de vogelgriep. Intervet Deutschland stelt de benodigde hoeveelheden ...
27 Apr 2006	Intervet versorgt deutsche Zoos mit Impfstoff gegen Vogelgrippe Deutschland hat auf Initiative mehrerer Bundesländer die Zustimmung der Europäischen Union zur Impfung von Zoovögeln gegen die Aviäre Influenza erhalten. Intervet Deutschland stellt allen am Impfprogramm ...
21 Apr 2006	DSM Nutritional Products buys CRINA feed additive business from Intervet International Intervet herewith publishes a press release by DSM.Kaiseraugst (CH), 21st April 2006 Intervet International and DSM Nutritional Products signed an agreement on sale and purchase of the CRINA business. ...
27 Mar 2006	Akzo Nobel Pharma preparing for the future Arnhem, the Netherlands, March 27, 2006 — Akzo Nobel’s Pharma group is aiming to deliver at least one major filing per year from its pipeline as it positions itself for solid growth. Speaking at today’s ...
16 Mar 2006	Dogs and Catfish? - New VFD drug for catfish expected to fuel demand for veterinary services & expertise Companion and large-animal veterinarians near major catfish-production areas of the United States may want to bone up on aquatic diseases to help meet the expected surge in demand for veterinary services.The ...
14 Mar 2006	FDA’s Approval of AQUAFLOR Marks New Era in Teamwork The U.S. Food and Drug Administration’s recent approval of AQUAFLOR® (florfenicol) Type A Medicated Article for catfish marked a significant milestone in the industry’s combined efforts to make more products ...
16 Feb 2006	Intervet levert vogelgriepvaccin aan Franse regering Gisteren heeft het Franse Ministerie van Landbouw de intentie aangekondigd om buitenloopeenden tegen het vogelgriepvirus te vaccineren in drie departementen langs de Atlantische kust (Landes, Loire atlantique ...
16 Feb 2006	Intervet liefert Impfstoff gegen Aviäre Influenza („Vogelgrippe“) an französische Regierung Gestern kündigte das französische Landwirtschaftsministerium die Absicht an, Freiland-Enten in drei westlichen Regionen von Frankreich (Landes, Loire atlantique und Vendée) gegen die Aviäre Influenza ...
16 Feb 2006	Intervet supplies Avian Influenza vaccine to French Government Yesterday the French Ministry of Agriculture announced the intention to vaccinate outdoor ducks against Avian Influenza in three western parts of France (Landes, Loire atlantique and Vendée). The French ...
16 Feb 2006	Intervet va fournir aux autorités françaises un vaccin vétérinaire contre la grippe aviaire Le ministère français de l’agriculture a annoncé le 15 février son intention de faire vacciner contre la grippe aviaire les canards élevés en plein air dans trois départements de l’ouest (Landes, Loire-Atlantique ...
10 Feb 2006	Intervet International bv acquires Foot and Mouth Disease vaccine factory from Bayer HealthCare AG Boxmeer, February 10, 2006 – Today, Intervet, the animal health business unit of Akzo Nobel, announced the agreement with Bayer HealthCare AG to acquire the Foot and Mouth Disease (FMD) vaccine factory ...
7 Feb 2006	Akzo Nobel 2005 net income improves as effective strategy drives revenue growth Main highlights Net income up at EUR 961 million Growth in all units—revenues from present operations up 6% Organon—returning to growth, investing in future product sales and pipeline Intervet—excellent ...
7 Feb 2006	Akzo Nobel nettoresultaat 2005 verbeterd – effectieve strategie motor achter omzetgroei Belangrijkste highlights Nettoresultaat gestegen naar EUR 961 mln Groei bij alle units—totale omzet uit huidige activiteiten 6% hoger Organon—terugkeer naar groei; investeren in toekomstige omzet en ...
7 Feb 2006	Strategic initiatives deliver strong growth and basis for new platform Organon Biosciences Boxmeer, the Netherlands, February 7, 2006 – Akzo Nobel NV has announced today that it intends to separate its pharmaceutical activities from its chemicals and coatings businesses. The aim is to create ...
7 Feb 2006	Strategische initiatieven leveren sterke groei en basis voor nieuwe platform Organon Biosciences Boxmeer, Nederland, 7 februari 2006 – Akzo Nobel NV heeft vandaag het voornemen aangekondigd de onderneming verder te laten gaan in de vorm van twee zelfstandige bedrijven. De humane en veterinaire farma ...
27 Jan 2006	Schering-Plough Animal Health Corporation Introduces New Product Application to Control Swine Respiratory Disease Schering-Plough Animal Health Corporation has introduced Nuflor® Oral 2.3% Concentrate Solution, the broadest spectrum oral antibiotic available for the treatment of several major causes of swine respiratory ...